Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Esperion (ESPR) announced that following meetings with the U.S. Food and Drug Administration, it has gained alignment on a regulatory path forward for initiating Phase 3 studies of bempedoic acid ...
The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial ...
INDICATION NEXLIZET and NEXLETOL are indicated: IMPORTANT SAFETY INFORMATION NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to bempedoic acid or ezetimibe or ...
He breaks down new studies about bempedoic acid as a station alternative and the latest on the artificial sweetener erythritol and risk of heart attack and stroke. Recent heart health news caught ...
for the exclusive rights to commercialize NEXLETOL ® (bempedoic acid) and NEXLIZET ® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion will ...
The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback